WESTMINSTER, Colo., Dec. 11 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on
the development and commercialization of small molecule therapeutics for
the treatment of cancer, today announced that Paul L. Berns, President and
CEO, will present a corporate overview at the 2008 JPMorgan Healthcare
Conference in San Francisco.
The Company's presentation will take place at 12:00 p.m. (Eastern) on
Thursday, January 10, 2008. There will be a live webcast of the
presentation, which will be accessible through a link posted on the Allos
website home page and investor relations section. The webcast will be
available for replay on Allos' website through January 25, 2008.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on the
development and commercialization of small molecule therapeutics for the
treatment of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in a
pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory
peripheral T-cell lymphoma. The PROPEL trial is being conducted under an
agreement reached with the U.S. Food and Drug Administration under its
special protocol assessment, or SPA process. The Company is also
investigating PDX in patients with non-small cell lung cancer and a range
of lymphoma sub-types. The Company's other product candidate is RH1, a
targeted chemotherapeutic agent currently being evaluated in a Phase 1
trial in patients with advanced solid tumors or non-Hodgkins Lymphoma
(NHL). For additional information, please visit the Company's website at
http://www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties. Additional information
concerning these forward-looking statements and other factors that may
cause actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Annual Report on Form 10-K for the year ended December 31,
2006 and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in the
presentation. All forward-looking statements are based on information
currently available to the Company on the date thereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of this
presentation, except as required by law.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com/
CONTACT:
Derek Cole, Vice President, Investor
Relations of Allos Therapeutics, Inc., +1-720-540-5367,
dcole@allos.com
|
